Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C8H12N4O4 |
Molecular Weight | 228.2053 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2
InChI
InChIKey=XAUDJQYHKZQPEU-KVQBGUIXSA-N
InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
Molecular Formula | C8H12N4O4 |
Molecular Weight | 228.2053 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://clinicaltrials.gov/ct2/show/NCT02907359 | https://www.ncbi.nlm.nih.gov/pubmed/31060979 | https://clinicaltrials.gov/ct2/show/NCT02348489 | https://www.businesswire.com/news/home/20151006006636/en/Astex-Pharmaceuticals-Announces-Orphan-Drug-Designation-Guadecitabine | https://astx.com/research-development/clinical-pipeline/guadecitabine-sgi-110-dnmt-inhibitor-solid-tumors/https://www.ncbi.nlm.nih.gov/pubmed/23369223Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021790s018lbl.pdf, www.ncbi.nlm.nih.gov/pubmed/20501800
Sources: https://clinicaltrials.gov/ct2/show/NCT02907359 | https://www.ncbi.nlm.nih.gov/pubmed/31060979 | https://clinicaltrials.gov/ct2/show/NCT02348489 | https://www.businesswire.com/news/home/20151006006636/en/Astex-Pharmaceuticals-Announces-Orphan-Drug-Designation-Guadecitabine | https://astx.com/research-development/clinical-pipeline/guadecitabine-sgi-110-dnmt-inhibitor-solid-tumors/https://www.ncbi.nlm.nih.gov/pubmed/23369223
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021790s018lbl.pdf, www.ncbi.nlm.nih.gov/pubmed/20501800
Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon administration the decitabine is metabolized to the active phosphorylated metabolite which is incorporated into DNA and thus inhibits DNA methyltransferase (decitabine deplete DNMT1).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
|||
Target ID: CHEMBL1993 Sources: www.ncbi.nlm.nih.gov/pubmed/20501800 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DACOGEN Approved UseDacogen is a nucleoside metabolic inhibitor indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate -2, and high-risk International Prognostic Scoring System groups. Launch Date1.14652794E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17564707 |
15 mg/m² steady-state, intravenous dose: 15 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DECITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
163 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17564707 |
15 mg/m² steady-state, intravenous dose: 15 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DECITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.62 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17564707 |
15 mg/m² steady-state, intravenous dose: 15 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DECITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99% |
DECITABINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg/m2 2 times / day steady, intravenous Highest studied dose Dose: 100 mg/m2, 2 times / day Route: intravenous Route: steady Dose: 100 mg/m2, 2 times / day Sources: |
unhealthy, 52 years (range: 23 - 78 years) n = 13 Health Status: unhealthy Condition: chronic myelogenous leukemia (CML) Age Group: 52 years (range: 23 - 78 years) Sex: M+F Population Size: 13 Sources: |
|
20 mg/m2 1 times / day steady, intravenous Recommended|MTD Dose: 20 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 59 years (range: 42–79 years) n = 6 Health Status: unhealthy Condition: unresectable liver-predominant metastases Age Group: 59 years (range: 42–79 years) Sex: M+F Population Size: 6 Sources: |
Other AEs: Anaemia, Lymphopenia... Other AEs: Anaemia (grade 1, 17%) Sources: Lymphopenia (grade 2, 17%) Neutropenia (grade 2, 17%) Leucopenia (grade 1, 17%) Thrombocytopaenia (grade 1, 17%) |
15 mg/m2 1 times / day steady, intravenous Dose: 15 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 1 times / day Sources: |
unhealthy, 61 years (range: 32–82 years) n = 16 Health Status: unhealthy Condition: CLL Age Group: 61 years (range: 32–82 years) Sex: M+F Population Size: 16 Sources: |
DLT: Hyperbilirubinemia, Thrombocytopenia... Dose limiting toxicities: Hyperbilirubinemia (grade 3, 2 patients) Sources: Thrombocytopenia (2 patients) |
20 mg/m2 1 times / day multiple, subcutaneous Dose: 20 mg/m2, 1 times / day Route: subcutaneous Route: multiple Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 65 years n = 14 Health Status: unhealthy Condition: myelodysplastic syndrome Age Group: 65 years Sex: M+F Population Size: 14 Sources: |
|
15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Disc. AE: Anemia, Neutropenia... Other AEs: Neutropenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Anemia (grade 5, 6 patients) Other AEs:Neutropenia (grade 5, 6 patients) Thrombocytopenia (grade 5, 6 patients) Neutropenia (grade 3-4, 87%) Sources: Thrombocytopenia (grade 3-4, 85%) Febrile neutropenia (grade 3-4, 23%) Leukopenia (grade 3-4, 22%) |
15 mg/m2 1 times / day steady, intravenous Dose: 15 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 1 times / day Sources: |
unhealthy, 72 years (range: 68–75 years) n = 4 Health Status: unhealthy Condition: NHL Age Group: 72 years (range: 68–75 years) Sex: M+F Population Size: 4 Sources: |
DLT: Febrile neutropenia... Dose limiting toxicities: Febrile neutropenia (grade 3-4, 2 patients) Sources: |
660 mg/m2 single, intravenous Highest studied dose Dose: 660 mg/m2 Route: intravenous Route: single Dose: 660 mg/m2 Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: chronic myelogenous leukemia Population Size: 7 Sources: |
|
15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Other AEs: Neutropenia, Thrombocytopenia... Other AEs: Neutropenia (all grades, 83%) Sources: Page: p. 82Thrombocytopenia (all grades, 81%) Anemia (all grades, 54%) Splenomegaly (all grades, 2%) Thrombocythaemia (all grades, 4%) Tachycardia (all grades, 1%) Pulmonary edema (all grades, 1%) Nausea (all grades, 22%) Constipation (all grades, 8%) Diarrhea (all grades, 16%) Vomiting (all grades, 8%) Abdominal pain (all grades, 4%) Oral mucosal petechiae (all grades, 5%) Stomatitis (all grades, 7%) Loose stools (all grades, 2%) Tongue ulceration (all grades, 5%) Dysphagia (all grades, 2%) Pyrexia (all grades, 16%) Fatigue (all grades, 18%) Asthenia (all grades, 4%) Fall (all grades, 1%) Hyperbilirubinaemia (all grades, 4%) Hepatomegaly (all grades, 1%) Cellulitis (all grades, 2%) Urinary tract infection (all grades, 1%) Alanine aminotransferase increased (all grades, 1%) Aspartate aminotransferase increased (all grades, 1%) Alkaline phosphatase increased (all grades, 1%) Hypocalcemia (all grades, 7%) Hypoalbuminemia (all grades, 7%) Hypomagnesaemia (all grades, 2%) Hypokalemia (all grades, 4%) Decreased appetite (all grades, 4%) Anorexia (all grades, 6%) Dehydration (all grades, 1%) Arthralgia (all grades, 1%) Back pain (all grades, 1%) Headache (all grades, 10%) Dizziness (all grades, 2%) Hypoaesthesia (all grades, 1%) Insomnia (all grades, 5%) Depression (all grades, 2%) Cough (all grades, 6%) Dyspnea (all grades, 2%) Pharyngitis (all grades, 4%) Epistaxis (all grades, 4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anaemia | grade 1, 17% | 20 mg/m2 1 times / day steady, intravenous Recommended|MTD Dose: 20 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 59 years (range: 42–79 years) n = 6 Health Status: unhealthy Condition: unresectable liver-predominant metastases Age Group: 59 years (range: 42–79 years) Sex: M+F Population Size: 6 Sources: |
Leucopenia | grade 1, 17% | 20 mg/m2 1 times / day steady, intravenous Recommended|MTD Dose: 20 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 59 years (range: 42–79 years) n = 6 Health Status: unhealthy Condition: unresectable liver-predominant metastases Age Group: 59 years (range: 42–79 years) Sex: M+F Population Size: 6 Sources: |
Thrombocytopaenia | grade 1, 17% | 20 mg/m2 1 times / day steady, intravenous Recommended|MTD Dose: 20 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 59 years (range: 42–79 years) n = 6 Health Status: unhealthy Condition: unresectable liver-predominant metastases Age Group: 59 years (range: 42–79 years) Sex: M+F Population Size: 6 Sources: |
Lymphopenia | grade 2, 17% | 20 mg/m2 1 times / day steady, intravenous Recommended|MTD Dose: 20 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 59 years (range: 42–79 years) n = 6 Health Status: unhealthy Condition: unresectable liver-predominant metastases Age Group: 59 years (range: 42–79 years) Sex: M+F Population Size: 6 Sources: |
Neutropenia | grade 2, 17% | 20 mg/m2 1 times / day steady, intravenous Recommended|MTD Dose: 20 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 20 mg/m2, 1 times / day Sources: |
unhealthy, 59 years (range: 42–79 years) n = 6 Health Status: unhealthy Condition: unresectable liver-predominant metastases Age Group: 59 years (range: 42–79 years) Sex: M+F Population Size: 6 Sources: |
Thrombocytopenia | 2 patients DLT |
15 mg/m2 1 times / day steady, intravenous Dose: 15 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 1 times / day Sources: |
unhealthy, 61 years (range: 32–82 years) n = 16 Health Status: unhealthy Condition: CLL Age Group: 61 years (range: 32–82 years) Sex: M+F Population Size: 16 Sources: |
Hyperbilirubinemia | grade 3, 2 patients DLT |
15 mg/m2 1 times / day steady, intravenous Dose: 15 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 1 times / day Sources: |
unhealthy, 61 years (range: 32–82 years) n = 16 Health Status: unhealthy Condition: CLL Age Group: 61 years (range: 32–82 years) Sex: M+F Population Size: 16 Sources: |
Leukopenia | grade 3-4, 22% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Febrile neutropenia | grade 3-4, 23% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Thrombocytopenia | grade 3-4, 85% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Neutropenia | grade 3-4, 87% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Anemia | grade 5, 6 patients Disc. AE |
15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Neutropenia | grade 5, 6 patients Disc. AE |
15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Thrombocytopenia | grade 5, 6 patients Disc. AE |
15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: |
unhealthy, 70 years (range: 65-76 years) n = 81 Health Status: unhealthy Condition: myelodysplastic syndromes Age Group: 70 years (range: 65-76 years) Sex: M+F Population Size: 81 Sources: |
Febrile neutropenia | grade 3-4, 2 patients DLT |
15 mg/m2 1 times / day steady, intravenous Dose: 15 mg/m2, 1 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 1 times / day Sources: |
unhealthy, 72 years (range: 68–75 years) n = 4 Health Status: unhealthy Condition: NHL Age Group: 72 years (range: 68–75 years) Sex: M+F Population Size: 4 Sources: |
Alanine aminotransferase increased | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Alkaline phosphatase increased | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Arthralgia | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Aspartate aminotransferase increased | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Back pain | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Dehydration | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Fall | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Hepatomegaly | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Hypoaesthesia | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Pulmonary edema | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Tachycardia | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Urinary tract infection | all grades, 1% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Headache | all grades, 10% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Diarrhea | all grades, 16% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Pyrexia | all grades, 16% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Fatigue | all grades, 18% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Cellulitis | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Depression | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Dizziness | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Dysphagia | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Dyspnea | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Hypomagnesaemia | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Loose stools | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Splenomegaly | all grades, 2% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Nausea | all grades, 22% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Abdominal pain | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Asthenia | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Decreased appetite | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Epistaxis | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Hyperbilirubinaemia | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Hypokalemia | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Pharyngitis | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Thrombocythaemia | all grades, 4% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Insomnia | all grades, 5% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Oral mucosal petechiae | all grades, 5% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Tongue ulceration | all grades, 5% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Anemia | all grades, 54% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Anorexia | all grades, 6% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Cough | all grades, 6% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Hypoalbuminemia | all grades, 7% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Hypocalcemia | all grades, 7% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Stomatitis | all grades, 7% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Constipation | all grades, 8% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Vomiting | all grades, 8% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Thrombocytopenia | all grades, 81% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Neutropenia | all grades, 83% | 15 mg/m2 3 times / day steady, intravenous Recommended Dose: 15 mg/m2, 3 times / day Route: intravenous Route: steady Dose: 15 mg/m2, 3 times / day Sources: Page: p. 82 |
unhealthy n = 83 Health Status: unhealthy Population Size: 83 Sources: Page: p. 82 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021790s000_Dacogen_BioPharmR.pdf#page=20 Page: 20.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
weak | ||||
Sources: https://pdf.hres.ca/dpd_pm/00049298.PDF#page=19 Page: 19.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
weak |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Unnatural enantiomers of 5-azacytidine analogues: syntheses and enzymatic properties. | 2000 Nov |
|
Demethylation by 5-aza-2'-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. | 2001 |
|
Applications of microarray technology in breast cancer research. | 2001 |
|
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. | 2001 Apr 3 |
|
Unnatural enantiomers of 5-azacytidine analogues: syntheses and enzymatic properties. | 2001 Apr-Jul |
|
Activation of the maternally preset program of apoptosis by microinjection of 5-aza-2'-deoxycytidine and 5-methyl-2'-deoxycytidine-5'-triphosphate in Xenopus laevis embryos. | 2001 Aug |
|
[Chemotherapy and radiation therapy]. | 2001 Dec |
|
Reexpression of a cluster of silenced transgenes is associated with their rearrangement. | 2001 Dec |
|
Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. | 2001 Dec 1 |
|
Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. | 2001 Feb 15 |
|
Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. | 2001 Jan 1 |
|
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. | 2001 Jan 11 |
|
Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites. | 2001 Jan 5 |
|
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. | 2001 Jul |
|
Transcription regulation and protein subcellular localization of the truncated basic hair keratin hHb1-DeltaN in human breast cancer cells. | 2001 Jun 22 |
|
Association of acetylated histones with paternally expressed genes in the Prader--Willi deletion region. | 2001 Mar 15 |
|
Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. | 2001 Oct |
|
DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. | 2001 Oct |
|
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. | 2001 Oct 1 |
|
CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. | 2001 Oct 15 |
|
Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. | 2001 Oct 26 |
|
Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. | 2001 Sep 10 |
|
Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture. | 2002 Feb 15 |
|
Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. | 2002 Feb 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02907359
Guadecitabine 60 mg/m2 given subcutaneously daily on Days 1-5 in 28-day cycles. The total amount (in mg) of guadecitabine to be administered is determined by body surface area.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 21:34:22 UTC 2023
by
admin
on
Thu Jul 06 21:34:22 UTC 2023
|
Record UNII |
776B62CQ27
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
555916
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
NCI_THESAURUS |
C1557
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
FDA ORPHAN DRUG |
227106
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
FDA ORPHAN DRUG |
159702
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
NDF-RT |
N0000000233
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
FDA ORPHAN DRUG |
122298
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
NCI_THESAURUS |
C2083
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
FDA ORPHAN DRUG |
123399
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
FDA ORPHAN DRUG |
537716
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
WHO-VATC |
QL01BC08
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/17/1881
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
DACOGEN (AUTHORIZED: LEUKEMIA, MYELOID)
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
FDA ORPHAN DRUG |
697019
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
LIVERTOX |
NBK548668
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
NDF-RT |
N0000175595
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
WHO-ATC |
L01BC08
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
||
|
FDA ORPHAN DRUG |
20687
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C981
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
DECITABINE
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
DB01262
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
776B62CQ27
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
SUB06932MIG
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
M4126
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1201129
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
50131
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
15657
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | RxNorm | ||
|
790
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
6805
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
776B62CQ27
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
2353-33-5
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
1165204
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
451668
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
C014347
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
Decitabine
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
6374
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
100000083471
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
DTXSID7030432
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
AA-24
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
219-089-4
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY | |||
|
127716
Created by
admin on Thu Jul 06 21:34:24 UTC 2023 , Edited by admin on Thu Jul 06 21:34:24 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
According to the limited data in the study by van Groeningen et al. (1986), decitabine is not excreted unchanged in urine.
|
||
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT | |||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ONCE DAILY |
|
||